APOA1 and atherosclerosis: One such application was studied by Mansukhani et al., who investigated the use of peptide amphiphile nanofibers containing the apolipoprotein A1 (Apo A1)-derived targeting peptide 4F as nanocarriers for Liver X receptor (LXR) delivery (ApoA1-LXR PA) in vivo and showed that supramolecular nanostructures can be used as safe and effective drug nanocarriers in the treatment of atherosclerosis [25].